Risk of tumorigenicity in mesenchymal stromal cell-based therapies--bridging scientific observations and regulatory viewpoints.
Barkholt L, Flory E, Jekerle V, Lucas-Samuel S, Ahnert P, Bisset L, Büscher D, Fibbe W, Foussat A, Kwa M, Lantz O, Mačiulaitis R, Palomäki T, Schneider CK, Sensebé L, Tachdjian G, Tarte K, Tosca L, Salmikangas P.
Barkholt L, et al.
Cytotherapy. 2013 Jul;15(7):753-9. doi: 10.1016/j.jcyt.2013.03.005. Epub 2013 Apr 18.
Cytotherapy. 2013.
PMID: 23602595
Review.